Pathogenesis of infection by human papillomavirus

Current Problems in Dermatology (Switzerland)

Volumn 45, Issue , 2014, Pages 47-57

  Brendle, Sarah A ^a   Bywaters, Stephanie M ^a   Christensen, Neil D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN;

ANUS CANCER; ARTICLE; BASEMENT MEMBRANE; CANCER RISK; CELL DIFFERENTIATION; CELL GROWTH; CODON USAGE; DISEASE ASSOCIATION; HOST; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; LIFE CYCLE; MOUTH CANCER; MOUTH CAVITY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SEXUALITY; SMOKING; TISSUE TROPISM; TROPISM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS; VIRUS CLASSIFICATION; VIRUS RELEASE; VIRUS SHEDDING; WART VIRUS; CLASSIFICATION; PAPILLOMA VIRUS; PATHOGENICITY; PHYSIOLOGY; VIRAL TROPISM; VIROLOGY;

HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; VIRAL TROPISM;

EID: 84922480365     PISSN: 14215721     EISSN: 16622944     Source Type: Book Series    
DOI: 10.1159/000355963     Document Type: Article

References (81)

1. De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004; 324: 17-27
2. Bravo IG, Alonso A: Phylogeny and evolution of papillomaviruses based on the E1 and E2 proteins. Virus Genes 2007; 34: 249-262
3. Bravo IG, de Sanjose S, Gottschling M: The clinical importance of understanding the evolution of papillomaviruses. Trends Microbiol 2010; 18: 432-438
4. Burk RD, Chen Z, Harari A, Smith BC, Kocjan BJ, Maver PJ, Poljak M: Classification and nomenclature system for human alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages. Acta Dermatovenerol Alp Panonica Adriat 2011; 20: 113-123
5. Bernard HU, Burk RD, Chen DK, van Hausen H, de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70-79
6. Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ: Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis 2013; 13: 75
7. Monteiro DL, Sodre FV, Russomano FB, Trajano AJ, Silva KS: Incidence of genital warts in adolescents and their association with cervical intraepithelial lesions. Eur J Obstet Gynecol Reprod Biol 2013; 168: 80-82
8. Jacobelli S, Laude H, Carlotti A, Rozenberg F, Deleuze J, Morini JP, Franck N, Gorin I, Avril MF, Dupin N: Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: A marker of human papillomavirus-related disorders not affected by antiretroviral therapy. Arch Dermatol 2011; 147: 590-596
9. Lowe SM, Katsidzira L, Meys R, Sterling JC, de Koning M, Quint W, Nathoo K, Munyati S, Ndhlovu SC, Salisbury JR, Bunker CB, Corbett EL, Miller RF, Ferrand RA: Acquired epidermodysplasia verruciformis due to multiple and unusual HPV infection among vertically infected, HIV-positive adolescents in Zimbabwe. Clin Infect Dis 2012; 54:e119-e123
10. Parkin DM, Bray F: Chapter 2: the burden of HPVrelated cancers. Vaccine 2006; 24(suppl 3):11-25
11. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE: Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011; 103: 368-383
12. Zandberg DP, Bhargava R, Badin S, Cullen KJ: The role of human papillomavirus in nongenital cancers. CA Cancer J Clin 2013; 63: 57-81
13. Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110: 525-541
14. Huang SH, Perez-Ordonez B, Weinreb I, Hope H, Massey C, Waldron JN, Kim J, Bayley AJ, Cummings B, Cho BC, Ringash J, Dawson LA, Siu LL, Chen C, Irish J, Gullane P, Hui A, Liu FF, Shen X, Xu W, O'Sullivan B: Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol 2013; 49: 79-85
15. Marur S, D'Souza H, Westra WH, Forastiere AA: HPV-associated head and neck cancer: A virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-789
16. Junor EJ, Kerr GR, Brewster DH: Oropharyngeal cancer. Fastest increasing cancer in Scotland, especially in men. BMJ 2010; 340:c2512
17. Ramqvist T, Dalianis T: Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 2010; 16: 1671-1677
18. Begum S, Westra WH: Basaloid squamous cell carcinoma of the head and neck is a mixed variant that can be further resolved by HPV status. Am J Surg Pathol 2008; 32: 1044-1050
19. Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, Buckland J, Sherman ME, Rydzak G, Kirk P, Lorincz AT, Wacholder S, Burk RD: A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1398-1409
20. Bonagura VR, Du Z, Ashouri E, Luo L, Hatam LJ, DeVoti JA, Rosenthal DW, Steinberg BM, Abramson AL, Gjertson DW, Reed EF, Rajalingam R: Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis. Hum Immunol 2010; 71: 212-219
21. Cornet I, Gheit T, Iannacone MR, Vignat J, Sylla BS, Del Mistro A, Franceschi S, Tommasino M, Clifford GM: HPV16 genetic variation and the development of cervical cancer worldwide. Br J Cancer 2013; 108: 240-244
22. Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, Koutsky LA: Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst 2006; 98: 1045-1052
23. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, Villa LL: High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007; 120: 1763-1768
24. Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrero R, Rodriguez A, Bratti MC, Sherman ME, Scarpidis U, Lin QQ, Terai M, Bromley RL, Buetow K, Apple RJ, Burk RD: Human papillomavirus type. variants and risk of cervical cancer. J Natl Cancer Inst 2001; 93: 315-318
25. Arroyo SL, Basaras M, Arrese E, Hernaez S, Andia D, Esteban V, Garcia-Etxebarria K, Jugo BM, Cisterna R: Human papillomavirus (HPV) genotype 18 variants in patients with clinical manifestations of HPV related infections in Bilbao, Spain. Virol J 2012; 9: 258
26. Godinez JM, Heideman DA, Gheit T, Alemany L, Snijders PJ, Tommasino M, Meijer CJ, De Sanjose S, Bosch FX, Bravo IG: Differential presence of papillomavirus variants in cervical cancer: an analysis for HPV33, HPV45 and HPV58. Infect Genet Evol 2013; 13: 96-104
27. Seitz H, Schmitt M, Bohmer G, Kopp-Schneider A, Muller M: Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. Int J Cancer 2013; 132:E139-E148
28. Chen Z, Schiffman M, Herrero R, Desalle R, Burk RD: Human papillomavirus (HPV) types 101 and isolated from cervicovaginal cells lack an E6 open reading frame (ORF) and are related to gamma-papillomaviruses. Virology 2007; 360: 447-453
29. Chen Z, Schiffman M, Herrero R, Burk RD: Identification and characterization of two novel human papillomaviruses (HPVs) by overlapping PCR: HPV102 and HPV106. J Gen Virol 2007; 88: 2952-2955
30. Chen Z, Schiffman M, Herrero R, Burk RD: Identification and characterization of two novel human papillomaviruses (HPVs) by overlapping PCR: HPV102 and HPV106. J Gen Virol 2007; 88: 2952-2955
31. De Villiers EM, Gunst K: Characterization of seven novel human papillomavirus types isolated from cutaneous tissue, but also present in mucosal lesions. J Gen Virol 2009; 90: 1999-2004
32. Nobre RJ, Herraez-Hernandez E, Fei JW, Langbein L, Kaden S, Grone HJ, de Villiers EM: E7 oncoprotein of novel human papillomavirus type 108 lacking the E6 gene induces dysplasia in organotypic keratinocyte cultures. J Virol 2009; 83: 2907-2916
33. Ekstrom J, Forslund O, Dillner J: Three novel papillomaviruses (HPV109, HPV112 and HPV114) and their presence in cutaneous and mucosal samples. Virology 2010; 397: 331-336
34. Chouhy D, Gorosito M, Sanchez A, Serra EC, Bergero A, Fernandez BR, Giri AA: New generic primer system targeting mucosal/genital and cutaneous human papillomaviruses leads to the characterization of HPV 115, a novel beta-papillomavirus species 3. Virology 2010; 397: 205-216
35. Li L, Barry P, Yeh E, Glaser C, Schnurr D, Delwart E: Identification of a novel human gammapapillomavirus species. J Gen Virol 2009; 90: 2413-2417
36. Kohler A, Gottschling M, Manning K, Lehmann MD, Schulz E, Kruger-Corcoran D, Stockfleth E, Nindl I: Genomic characterization of ten novel cutaneous human papillomaviruses from keratotic lesions of immunosuppressed patients. J Gen Virol 2011; 92: 1585-1594
37. Vasiljevic N, Hazard K, Dillner J, Forslund O: Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. J Gen Virol 2008; 89: 2467-2474
38. Schiller JT, Day PM, Kines RC: Current understanding of the mechanism of HPV infection. Gynecol Oncol 2010; 118:S12-S17
39. Culp TD, Budgeon LR, Marinkovich MP, Meneguzzi G, Christensen ND: Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol 2006; 80: 8940-8950
40. Smith JL, Campos SK, Ozbun MA: Human papillomavirus type 31 uses a caveolin 1-and dynamin 2-mediated entry pathway for infection of human keratinocytes. J Virol 2007; 81: 9922-9931
41. McBride AA: Replication and partitioning of papillomavirus genomes. Adv Virus Res 2008; 72: 155-205
42. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF: Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog 2009; 5:e1000318
43. Parish JL, Bean AM, Park RB, Androphy EJ: ChlR1 is required for loading papillomavirus E2 onto mitotic chromosomes and viral genome maintenance. Mol Cell 2006; 24: 867-876
44. You J, Croyle JL, Nishimura A, Ozato K, Howley PM: Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004; 117: 349-360
45. Madison KC: Barrier function of the skin: 'la raison d'etre' of the epidermis. J Invest Dermatol 2003; 121: 231-241
46. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT: Differentiation-dependent upregulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev 1995; 9: 2335-2349
47. Bedell MA, Hudson JB, Golub TR, Turyk ME, Hosken M, Wilbanks GD, Laimins LA: Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J Virol 1991; 65: 2254-2260
48. Stanley MA: Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 2012; 25: 215-222
49. Grabowska AK, Riemer AB: The invisible enemy-how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J 2012; 6: 249-256
50. Zhao KN, Chen J: Codon usage roles in human papillomavirus. Rev Med Virol 2011; 21: 397-411
51. Matthews K, Leong CM, Baxter L, Inglis E, Yun K, Backstrom BT, Doorbar J, Hibma M: Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol 2003; 77: 8378-8385
52. D'Costa ZJ, Jolly C, Androphy EJ, Mercer A, Matthews CM, Hibma MH: Transcriptional repression of E-cadherin by human papillomavirus type 16 E6. PLoS One 2012; 7:e48954
53. Ashrafi GH, Tsirimonaki E, Marchetti B, O'Brien PM, Sibbet GJ, Andrew L, Campo MS: Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 2002; 21: 248-259
54. Brady CS, Bartholomew JS, Burt DJ, Duggan-Keen MF, Glenville S, Telford N, Little AM, Davidson JA, Jimenez P, Ruiz-Cabello F, Garrido F, Stern PL: Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 2000; 55: 401-411
55. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M: TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007; 178: 3186-3197
56. Martin CM, O'Leary JJ: Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet Gynaecol 2011; 25: 605-615
57. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA: The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30(suppl 5): F55-F70
58. Yu T, Ferber MJ, Cheung TH, Chung TK, Wong YF, Smith DI: The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet 2005; 158: 27-34
59. Wentzensen N, Ridder R, Klaes R, Vinokurova S, Schaefer U, Doeberitz M: Characterization of viralcellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene 2002; 21: 419-426
60. Badaracco G, Venuti A, Sedati A, Marcante ML: HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness. J Med Virol 2002; 67: 574-582
61. Fu L, van Doorslaer K, Chen Z, Ristriani T, Masson M, Trave G, Burk RD: Degradation of p53 by human alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity. PLoS One 2010; 5:e12816
62. Zanier K, ould M'hamed ould Sidi A, Boulade-Ladame C, Rybin V, Chappelle A, Atkinson A, Kieffer B, Trave G: Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53. Structure 2012; 20: 604-617
63. Pim D, Banks L: Interaction of viral oncoproteins with cellular target molecules: infection with highrisk vs low-risk human papillomaviruses. APMIS 2010; 118: 471-493
64. Barrow-Laing L, Chen W, Roman A: Low-and highrisk human papillomavirus E7 proteins regulate p130 differently. Virology 2010; 400: 233-239
65. Turner CF, Danella RD, Rogers SM: Sexual behavior in the United States 1930-1990: trends and methodological problems. Sex Transm Dis 1995; 22: 173-190
66. Herbenick D, Reece M, Schick V, Sanders SA, Dodge B, Fortenberry JD: Sexual behavior in the United States: results from a national probability sample of men and women ages 14-94. J Sex Med 2010; 7(suppl 5): 255-265
67. Bajos N, Bozon M, Beltzer N, Laborde C, Andro A, Ferrand M, Goulet V, Laporte A, Le Van C, Leridon H, Levinson S, Razafindratsima N, Toulemon L, Warszawski J, Wellings K: Changes in sexual behaviours: from secular trends to public health policies. AIDS 2010; 24: 1185-1191
68. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML: Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009; 199: 1263-1269
69. Frisch M, Melbye M, Moller H: Trends in incidence of anal cancer in Denmark. BMJ 1993; 306: 419-422
70. Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, Ashley RL, Beagrie M, Ryan JA, Corey L: Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987; 317: 973-977
71. Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Mao EJ, Fitzgibbons ED, Huang S, Beckmann AM, McDougall JK, Galloway DA: Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90: 1626-1636
72. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernandez L, Idris A, Sanchez MJ, Nieto A, Talamini R, Tavani A, Bosch FX, Reidel U, Snijders PJ, Meijer CJ, Viscidi R, Munoz N, Franceschi S: Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-1783
73. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420
74. Smith EM, Ritchie JM, Summersgill KF, Hoffman HT, Wang DH, Haugen TH, Turek LP: Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004; 96: 449-455
75. Giuliano AR, Sedjo RL, Roe DJ, Harri R, Baldwi S, Papenfuss MR, Abrahamsen M, Inserra P: Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002; 13: 839-846
76. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR: Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004; 101: 281-288
77. De Sanjosé S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 2007; 7: 453-459
78. Smith EM, Capogrossi KL, Estabrooks PA: School wellness policies: effects of using standard templates. Am J Prev Med 2012; 43: 304-308
79. Adler DH, Kakinami L, Modisenyane T, Tshabangu N, Mohapi L, De Bruyn G, Martinson NA, Omar T: Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART. AIDS 2012; 26: 1645-1652
80. Anaya-Saavedra G, Flores-Moreno B, Garcia-Carranca A, Irigoyen-Camacho E, Guido-Jimenez M, Ramirez-Amador V: HPV oral lesions in HIV-infected patients: the impact of long-term HAART. J Oral Pathol Med 2013; 42: 443-449
81. Beachler DC, Weber KM, Margolick JB, Strickler HD, Cranston RD, Burk RD, Wiley DJ, Minkoff H, Reddy S, Stammer EE, Gillison ML, D'Souza G: Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIVnegative adults. Cancer Epidemiol Biomarkers Prev 2012; 21: 122-133.